Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises 1Vision Biogas on its public offer for Biokraft
Mandate

Vinge advises 1Vision Biogas on its public offer for Biokraft

February 05, 2024 Capital Markets and Public M&A M&A FDI EU, Competition and Regulatory

1Vision Biogas AB, a company controlled by Aneo, HitecVision and St1, has made a public mandatory bid for all shares in Biokraft International AB. The offer values the shares of Biokraft at approximately SEK 900 million. Vinge advises 1Vision Biogas.

The Vinge team includes Christian Lindhé, Erik Sjöman, Martin Madsen Svanberg, Johan Åhman and Johan Severinsson (Capital Markets and Public M&A), Jesper Ottergren (M&A) as well as Sofie Nordgren, Pär Remnelid, Rikard Azelius and Jasmine Elgh (FDI/EU, Competition and Regulatory).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

 Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026

Vinge has advised IK Partners in connection with the acquisition of Selatek

 Vinge has advised IK Partners (“IK”) in connection with IK X Fund’s acquisition of SELATEK Holding AB (“Selatek”), a leading Swedish technical installation platform, from Amplio Private Equity AB and the minority shareholders.
April 20, 2026